<DOC>
	<DOCNO>NCT00161746</DOCNO>
	<brief_summary>The purpose study evaluate ) whether seroconversion rate child equivalent two and/or three partial vaccination TICOVAC 0.25 mL TICOVAC 0.5 mL , b ) whether difference term safety two product .</brief_summary>
	<brief_title>Safety Immunogenicity Study 3 Vaccinations With TICOVAC 2 Dosages Healthy Children Aged Between 6 Months 3 Years</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<criteria>Male female child age 6 47 month No history previous TBE vaccination Clinically healthy Informed consent provide parent History allergic reaction , particular allergic reaction one component vaccine Suffering disease effectively treat stabilised Suffering disease undergo form treatment expect influence immunological function Suffering chronic , degenerative and/or inflammatory disease central nervous system HIVpositivity ( special HIV test require purpose study ) Suffering febrile disease History vaccination yellow fever and/or Japanese encephalitis Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tick-Borne Encephalitis</keyword>
</DOC>